Cybin Reveals Grant Of Two Additional Patents In Japan In Support Of Its DMT Program
Portfolio Pulse from Benzinga Newsdesk
Cybin has been granted two additional patents in Japan, enhancing its DMT program aimed at treating Generalized Anxiety Disorder. These patents, securing exclusivity until at least 2040 and 2041, cover a synthesis method for DMT and dDMT and injectable formulations.
February 07, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin's acquisition of two additional patents in Japan for its DMT program could significantly bolster its position in the mental health treatment market, particularly for Generalized Anxiety Disorder.
The granting of these patents not only strengthens Cybin's intellectual property portfolio but also enhances its competitive edge in the mental health treatment sector. The exclusivity provided until at least 2040 and 2041 for the synthesis method and injectable formulations could lead to significant advancements in the treatment of Generalized Anxiety Disorder, potentially increasing investor confidence and stock value in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90